Dr. Reddy’s Laboratories receives five observations following USFDA inspection at Srikakulam facility | Business Upturn

Top Stories

Torrent Pharma, Dr. Reddy’s and Zydus Life benefit as generic Semaglutide market share rises to 33% within 10 days of launch Trent shares surge in otherwise weak market as board to consider first-ever bonus issue on April 22 ICICI Bank shares surge as the top Nifty gainer today after Q4 FY26 results beat estimates, provisions decline sharply IEX shares slip over 5% after CERC floats market coupling document again Motilal Oswal advises to Buy CG Power, Atlanta Electricals and GE Vernova shares for significant upside as multi-year capex cycle remains intact Aavas Financiers shares in focus as MD & CEO resigns effective immediately ICICI Bank shares in focus tomorrow and likely to react positively after Q4; profit rises, provisions sharply decline Top Q4 FY26 results to watch next week: From HCL Tech, Trent and Infosys to Axis Bank, IndusInd and UltraTech — your complete earnings calendar Torrent Pharma, Dr. Reddy’s and Zydus Life benefit as generic Semaglutide market share rises to 33% within 10 days of launch Trent shares surge in otherwise weak market as board to consider first-ever bonus issue on April 22 ICICI Bank shares surge as the top Nifty gainer today after Q4 FY26 results beat estimates, provisions decline sharply IEX shares slip over 5% after CERC floats market coupling document again Motilal Oswal advises to Buy CG Power, Atlanta Electricals and GE Vernova shares for significant upside as multi-year capex cycle remains intact Aavas Financiers shares in focus as MD & CEO resigns effective immediately ICICI Bank shares in focus tomorrow and likely to react positively after Q4; profit rises, provisions sharply decline Top Q4 FY26 results to watch next week: From HCL Tech, Trent and Infosys to Axis Bank, IndusInd and UltraTech — your complete earnings calendar

HOME /BUSINESS/CORPORATES

Dr. Reddy’s Laboratories has announced that the United States Food & Drug Administration (USFDA) has completed a comprehensive GMP and Pre-Approval Inspection (PAI) at its formulations facility, FTO-SEZ PU01, located in Srikakulam, Andhra Pradesh. The inspection took place between 4 December and 12 December 2025 and concluded with the issuance of a Form 483 containing five observations.

The company noted that the observations are addressable and fall within the scope of routine regulatory compliance. Dr. Reddy’s has stated that it is committed to responding to the USFDA within the prescribed timeline and implementing all necessary corrective and preventive actions to ensure full alignment with global quality standards.

In the meantime, Dr. Reddy’s Laboratories ended the session at ₹1,280, slightly above its opening price of ₹1,275. The stock touched an intraday high of ₹1,280.40 and a low of ₹1,267.30.

Add us as preferred source on Google

TOPICS: Dr Reddy's Laboratories